AlphAIalphai — Financial news for AI agents
Stock TitanMAR 172 min read$GPMT

Granite Point (NYSE: GPMT) GC nets shares after RSU vesting

Michael J. Karber, General Counsel and Secretary of Granite Point Mortgage Trust (NYSE: GPMT), exercised 19,213 restricted stock units (RSUs) on March 15, 2026. A total of 9,452 shares were withheld for tax obligations, resulting in him directly holding 123,371 common shares. These RSUs were part of a 57,638-unit grant from March 15, 2023, with the final 34% vesting on March 15, 2026.

Original reporting
Stock Titan
Published Mar 17, 2026, 4:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 17, 2026, 5:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Granite Point (NYSE: GPMT) GC nets shares after RSU vesting — source image
Source · Stock Titan
Decision brief

The 30-second read

$GPMTNeutralLow
01

Why it matters

This activity is typical and does not indicate a significant change in company outlook.

02

Market read

Low relevance for short-term trading; more relevant for understanding insider confidence over the longer term.

03

What to watch

Potential tax implications for insiders and broader market conditions could influence stock movement in the future.

Timing: short-term

Background

Michael J. Karber, General Counsel and Secretary of GPMT, exercised RSUs, a routine form of compensation and insider activity.

Company-level read

Ticker impact

$GPMTNeutralMedium confidence
Context

Insider stock activity related to RSU vesting

Expected impact

Minimal immediate price movement expected

Evidence & confidence

RSU exercises are routine and do not necessarily signal a change in company fundamentals; market reaction is likely limited.

Market effects

Sector

Limited sector impact; insider activity is company-specific

Regional

Negligible regional effects

Global

Minimal

Counterpoint

What could challenge this read

Some traders might interpret insider exercises as a sign of confidence and consider accumulating shares, but evidence is limited.

Key entities

  • Company
    Granite Point Mortgage Trust

    A real estate investment trust focused on mortgage loans.

  • Individual
    Michael J. Karber

    General Counsel and Secretary of GPMT.

Read at source← All news

Related articles

AUG 13
$GPMTMedAI 8/10

Granite Point Mortgage Trust (GPMT) Q2 2026 Earnings Call Transcript

Granite Point Mortgage Trust (GPMT) reported Q2 2026 results on an earnings call. GAAP net loss was $62 million ($1.29/share) and distributable loss $37.7 million ($0.79/share). Book value fell to $5.70/share. CECL reserve rose to $165.8 million (11.4% of commitments). Management discussed legacy loan resolutions, JPMorgan CLO refinancing, and covenant cash levels.

fool.com7 min
AUG 9
$GPMTMed

Granite Point Mortgage Trust Q2 Earnings Call Highlights

Granite Point Mortgage Trust (NYSE:GPMT) reported Q2 updates on reserves and loan resolutions. About 78% of its allowance was for individually assessed loans. It had $253m principal on five risk-rated loans with CECL reserves of ~$120m (47.4%). The quarter saw ~$122m net portfolio reduction, $58m unrestricted cash, and leverage of 1.9x.

yahoo.com7 min
AUG 5
$GPMTMed

Granite Point Mortgage Trust Inc. (GPMT): Results of Operations and Financial Condition

Granite Point Mortgage Trust Inc. (GPMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Granite Point Mortgage Trust Inc. Reports Second Quarter 2026 Financial Results and Post Quarter-End Update NEW YORK, August 5, 2026 – Granite Point Mortgage Trust Inc. (NYSE: GPMT) ("GPMT," "Granite Point" or the "Company") today announced its financial results for the quarter e

SEC EDGAR 8-K6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min
SEP 8
$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

yahoo.com2 min